Skip to main content
Erschienen in: Inflammation 4/2022

28.03.2022 | Original Article

Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients

verfasst von: Marjan Golabi, Farshid Fathi, Morteza Samadi, Mohammad Sadegh Hesamian, Nahid Eskandari

Erschienen in: Inflammation | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) is described as an immune disorder with inflammation and neurodegeneration. Relapsing–remitting MS (RRMS) is one of the most common types of MS. The diagnostic manner for this disorder typically includes the usage of magnetic resonance imaging (MRI); however, this is not always a very precise diagnostic method. Identification of molecular biomarkers in RRMS body fluids samples compared to healthy subjects can be useful to indicate the normal and pathogenic biological processes or pharmacological responses to drug interaction. In this regard, this study evaluated different miRNAs in isolated peripheral blood mononuclear cells (PBMCs) of RRMS compared to controls and their correlations with altered T regulatory type 1 (Tr1) cells, osteopontin (OPN), and interleukin 10 (IL-10) levels. The frequency of Tr1 cells was measured using flow cytometry. Also, the expressions of different miRNAs were evaluated via quantitative real-time polymerase chain reaction (RT-qPCR) and plasma levels of IL-10 and OPN were tested by enzyme-linked immunosorbent assay (ELISA). The obtained results showed the Tr1 cells’ frequency, Let7c-5p, and miR-299-5p levels decreased in RRMS patients to about 59%, 0.69%, and 20% of HCs, respectively, (P < 0.05). The miR-106a-5p levels increased about 7.5-fold in RRMS patients in comparison to HCs (P < 0.05). Moreover, the results showed that there was an increased negative association between Tr1 frequency and plasma-OPN levels in RRMS patients in comparison to HCs and also, we found a moderate positive correlation between plasma-IL-10 and miR-299-5p expression of RRMS patients. Overall, it may be possible to use these biomarkers to improve the diagnostic process. These biomarkers may also be considered for clinical and therapeutic studies in the future.

Graphical abstract

Literatur
1.
Zurück zum Zitat Trapp, B.D., and K.-A. Nave. 2008. Multiple sclerosis: An immune or neurodegenerative disorder? Annual Review of Neuroscience 31: 247–269.CrossRef Trapp, B.D., and K.-A. Nave. 2008. Multiple sclerosis: An immune or neurodegenerative disorder? Annual Review of Neuroscience 31: 247–269.CrossRef
2.
Zurück zum Zitat Lublin, F.D., S.C. Reingold, J.A. Cohen, G.R. Cutter, P.S. Sørensen, A.J. Thompson, et al. 2014. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83 (3): 278–286.CrossRef Lublin, F.D., S.C. Reingold, J.A. Cohen, G.R. Cutter, P.S. Sørensen, A.J. Thompson, et al. 2014. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83 (3): 278–286.CrossRef
3.
Zurück zum Zitat Rocca, M.A., P. Valsasina, V. Martinelli, P. Misci, A. Falini, G. Comi, et al. 2012. Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology 79 (14): 1449–1457.CrossRef Rocca, M.A., P. Valsasina, V. Martinelli, P. Misci, A. Falini, G. Comi, et al. 2012. Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology 79 (14): 1449–1457.CrossRef
4.
Zurück zum Zitat Dobson, R., and G. Giovannoni. 2019. Multiple sclerosis—a review. European journal of neurology. 26 (1): 27–40.CrossRef Dobson, R., and G. Giovannoni. 2019. Multiple sclerosis—a review. European journal of neurology. 26 (1): 27–40.CrossRef
5.
Zurück zum Zitat Dilokthornsakul, P., R.J. Valuck, K.V. Nair, J.R. Corboy, R.R. Allen, and J.D. Campbell. 2016. Multiple sclerosis prevalence in the United States commercially insured population. Neurology 86 (11): 1014–1021.CrossRef Dilokthornsakul, P., R.J. Valuck, K.V. Nair, J.R. Corboy, R.R. Allen, and J.D. Campbell. 2016. Multiple sclerosis prevalence in the United States commercially insured population. Neurology 86 (11): 1014–1021.CrossRef
6.
Zurück zum Zitat Hosseinzadeh, A., M. Baneshi, B. Sedighi, J. Kermanchi, and A. Haghdoost. 2019. Incidence of multiple sclerosis in Iran: A nationwide, population-based study. Public Health 175: 138–144.CrossRef Hosseinzadeh, A., M. Baneshi, B. Sedighi, J. Kermanchi, and A. Haghdoost. 2019. Incidence of multiple sclerosis in Iran: A nationwide, population-based study. Public Health 175: 138–144.CrossRef
7.
Zurück zum Zitat Venken, K., N. Hellings, T. Broekmans, K. Hensen, J.-L. Rummens, and P. Stinissen. 2008. Natural naive CD4+ CD25+ CD127 low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression. The Journal of Immunology. 180 (9): 6411–6420.CrossRef Venken, K., N. Hellings, T. Broekmans, K. Hensen, J.-L. Rummens, and P. Stinissen. 2008. Natural naive CD4+ CD25+ CD127 low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression. The Journal of Immunology. 180 (9): 6411–6420.CrossRef
8.
Zurück zum Zitat Campbell, G.R., J.T. Worrall, and D.J. Mahad. 2014. The central role of mitochondria in axonal degeneration in multiple sclerosis. Multiple Sclerosis Journal. 20 (14): 1806–1813.CrossRef Campbell, G.R., J.T. Worrall, and D.J. Mahad. 2014. The central role of mitochondria in axonal degeneration in multiple sclerosis. Multiple Sclerosis Journal. 20 (14): 1806–1813.CrossRef
9.
Zurück zum Zitat Mahad, D.H., B.D. Trapp, and H. Lassmann. 2015. Pathological mechanisms in progressive multiple sclerosis. The Lancet Neurology. 14 (2): 183–193.CrossRef Mahad, D.H., B.D. Trapp, and H. Lassmann. 2015. Pathological mechanisms in progressive multiple sclerosis. The Lancet Neurology. 14 (2): 183–193.CrossRef
10.
Zurück zum Zitat Brück, W. 2005. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. Journal of neurology. 252 (5): v10–v15.CrossRef Brück, W. 2005. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. Journal of neurology. 252 (5): v10–v15.CrossRef
11.
Zurück zum Zitat Lassmann, H., J. Van Horssen, and D. Mahad. 2012. Progressive multiple sclerosis: Pathology and pathogenesis. Nature Reviews Neurology. 8 (11): 647–656.CrossRef Lassmann, H., J. Van Horssen, and D. Mahad. 2012. Progressive multiple sclerosis: Pathology and pathogenesis. Nature Reviews Neurology. 8 (11): 647–656.CrossRef
12.
Zurück zum Zitat Astier, A.L., and D.A. Hafler. 2007. Abnormal Tr1 differentiation in multiple sclerosis. Journal of neuroimmunology. 191 (1–2): 70–78.CrossRef Astier, A.L., and D.A. Hafler. 2007. Abnormal Tr1 differentiation in multiple sclerosis. Journal of neuroimmunology. 191 (1–2): 70–78.CrossRef
13.
Zurück zum Zitat Ireland, S.J., N.L. Monson, and L.S. Davis. 2015. Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10. Cytokine 73 (2): 236–244.CrossRef Ireland, S.J., N.L. Monson, and L.S. Davis. 2015. Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10. Cytokine 73 (2): 236–244.CrossRef
14.
Zurück zum Zitat Mari, E.R., J.N. Moore, G.X. Zhang, and A. Rostami. 2015. Mechanisms of immunological tolerance in central nervous system inflammatory demyelination. Clinical and Experimental Neuroimmunology. 6 (3): 264–274.CrossRef Mari, E.R., J.N. Moore, G.X. Zhang, and A. Rostami. 2015. Mechanisms of immunological tolerance in central nervous system inflammatory demyelination. Clinical and Experimental Neuroimmunology. 6 (3): 264–274.CrossRef
15.
Zurück zum Zitat Hur, E.M., S. Youssef, M.E. Haws, S.Y. Zhang, R.A. Sobel, and L. Steinman. 2007. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature immunology. 8 (1): 74–83.CrossRef Hur, E.M., S. Youssef, M.E. Haws, S.Y. Zhang, R.A. Sobel, and L. Steinman. 2007. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature immunology. 8 (1): 74–83.CrossRef
16.
Zurück zum Zitat Jansson, M., V. Panoutsakopoulou, J. Baker, L. Klein, and H. Cantor. 2002. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. The Journal of Immunology. 168 (5): 2096–2099.CrossRef Jansson, M., V. Panoutsakopoulou, J. Baker, L. Klein, and H. Cantor. 2002. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. The Journal of Immunology. 168 (5): 2096–2099.CrossRef
17.
Zurück zum Zitat Kasinski, A.L., and F.J. Slack. 2011. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer. 11 (12): 849–864.CrossRef Kasinski, A.L., and F.J. Slack. 2011. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer. 11 (12): 849–864.CrossRef
18.
Zurück zum Zitat Tufekci, K.U., M.G. Oner, S. Genc, and K. Genc. 2011. MicroRNAs and multiple sclerosis. Autoimmune diseases. 2011. Tufekci, K.U., M.G. Oner, S. Genc, and K. Genc. 2011. MicroRNAs and multiple sclerosis. Autoimmune diseases. 2011.
19.
Zurück zum Zitat Gandhi, R., B. Healy, T. Gholipour, S. Egorova, A. Musallam, M.S. Hussain, et al. 2013. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Annals of neurology. 73 (6): 729–740.CrossRef Gandhi, R., B. Healy, T. Gholipour, S. Egorova, A. Musallam, M.S. Hussain, et al. 2013. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Annals of neurology. 73 (6): 729–740.CrossRef
20.
Zurück zum Zitat Sharma, A., M. Kumar, J. Aich, M. Hariharan, S.K. Brahmachari, A. Agrawal, et al. 2009. Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proceedings of the National Academy of Sciences. 106 (14): 5761–5766.CrossRef Sharma, A., M. Kumar, J. Aich, M. Hariharan, S.K. Brahmachari, A. Agrawal, et al. 2009. Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proceedings of the National Academy of Sciences. 106 (14): 5761–5766.CrossRef
21.
Zurück zum Zitat Jiang, L., Z. Cheng, S. Qiu, Z. Que, W. Bao, C. Jiang, et al. 2012. Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. International immunopharmacology. 14 (2): 217–223.CrossRef Jiang, L., Z. Cheng, S. Qiu, Z. Que, W. Bao, C. Jiang, et al. 2012. Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. International immunopharmacology. 14 (2): 217–223.CrossRef
22.
Zurück zum Zitat Shevde, L.A., B.J. Metge, A. Mitra, Y. Xi, J. Ju, J.A. King, et al. 2010. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299–5p regulated de novo expression of osteopontin. Journal of cellular and molecular medicine. 14 (6b): 1693–1706.CrossRef Shevde, L.A., B.J. Metge, A. Mitra, Y. Xi, J. Ju, J.A. King, et al. 2010. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299–5p regulated de novo expression of osteopontin. Journal of cellular and molecular medicine. 14 (6b): 1693–1706.CrossRef
23.
Zurück zum Zitat Hung, P.-S., F.-C. Chen, S.-H. Kuang, S.-Y. Kao, S.-C. Lin, and K.-W. Chang. 2010. miR-146a induces differentiation of periodontal ligament cells. Journal of dental research. 89 (3): 252–257.CrossRef Hung, P.-S., F.-C. Chen, S.-H. Kuang, S.-Y. Kao, S.-C. Lin, and K.-W. Chang. 2010. miR-146a induces differentiation of periodontal ligament cells. Journal of dental research. 89 (3): 252–257.CrossRef
24.
Zurück zum Zitat Hurst, D.R., M.D. Edmonds, G.K. Scott, C.C. Benz, K.S. Vaidya, and D.R. Welch. 2009. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer research. 69 (4): 1279–1283.CrossRef Hurst, D.R., M.D. Edmonds, G.K. Scott, C.C. Benz, K.S. Vaidya, and D.R. Welch. 2009. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer research. 69 (4): 1279–1283.CrossRef
25.
Zurück zum Zitat Tang, H., Y. Lai, J. Zheng, K. Chen, H. Jiang, and G. Xu. 2020. miR-146a promotes tolerogenic properties of dendritic cells and through targeting Notch1 signaling. Immunological investigations. 49 (5): 555–570.CrossRef Tang, H., Y. Lai, J. Zheng, K. Chen, H. Jiang, and G. Xu. 2020. miR-146a promotes tolerogenic properties of dendritic cells and through targeting Notch1 signaling. Immunological investigations. 49 (5): 555–570.CrossRef
26.
Zurück zum Zitat Csepany, T. 2018. Diagnosis of multiple sclerosis: A review of the 2017 revisions of the McDonald criteria. Ideggyogyaszati szemle. 71 (9–10): 321–329.CrossRef Csepany, T. 2018. Diagnosis of multiple sclerosis: A review of the 2017 revisions of the McDonald criteria. Ideggyogyaszati szemle. 71 (9–10): 321–329.CrossRef
27.
Zurück zum Zitat Calabresi, P.A. 2004. Diagnosis and management of multiple sclerosis. American family physician. 70 (10): 1935–1944.PubMed Calabresi, P.A. 2004. Diagnosis and management of multiple sclerosis. American family physician. 70 (10): 1935–1944.PubMed
28.
Zurück zum Zitat Hauser, S.L. 1994. Multiple sclerosis and other demyelinating diseases. Harrison’s principles of internal medicine. 1994;2287. Hauser, S.L. 1994. Multiple sclerosis and other demyelinating diseases. Harrison’s principles of internal medicine. 1994;2287.
29.
Zurück zum Zitat Montalban, X., M. Tintore, J. Swanton, F. Barkhof, F. Fazekas, M. Filippi, et al. 2010. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74 (5): 427–434.CrossRef Montalban, X., M. Tintore, J. Swanton, F. Barkhof, F. Fazekas, M. Filippi, et al. 2010. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74 (5): 427–434.CrossRef
30.
Zurück zum Zitat Comabella, M., I. Pericot, R. Goertsches, C. Nos, M. Castillo, J.B. Navarro, et al. 2005. Plasma osteopontin levels in multiple sclerosis. Journal of neuroimmunology. 158 (1–2): 231–239.CrossRef Comabella, M., I. Pericot, R. Goertsches, C. Nos, M. Castillo, J.B. Navarro, et al. 2005. Plasma osteopontin levels in multiple sclerosis. Journal of neuroimmunology. 158 (1–2): 231–239.CrossRef
31.
Zurück zum Zitat Zaffran, Y., O. Destaing, A. Roux, S. Ory, T. Nheu, P. Jurdic, et al. 2001. CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. The Journal of Immunology. 167 (12): 6780–6785.CrossRef Zaffran, Y., O. Destaing, A. Roux, S. Ory, T. Nheu, P. Jurdic, et al. 2001. CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. The Journal of Immunology. 167 (12): 6780–6785.CrossRef
32.
Zurück zum Zitat Dai, H., B. Ciric, G.-X. Zhang, and A. Rostami. 2012. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor. Journal of neuroimmunology. 245 (1–2): 1–7.CrossRef Dai, H., B. Ciric, G.-X. Zhang, and A. Rostami. 2012. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor. Journal of neuroimmunology. 245 (1–2): 1–7.CrossRef
33.
Zurück zum Zitat Ma, A., Z. Xiong, Y. Hu, S. Qi, L. Song, H. Dun, et al. 2009. Dysfunction of IL-10-producing type 1 regulatory T cells and CD4+ CD25+ regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys. International immunopharmacology. 9 (5): 599–608.CrossRef Ma, A., Z. Xiong, Y. Hu, S. Qi, L. Song, H. Dun, et al. 2009. Dysfunction of IL-10-producing type 1 regulatory T cells and CD4+ CD25+ regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys. International immunopharmacology. 9 (5): 599–608.CrossRef
34.
Zurück zum Zitat Martinez‐Forero, I., R. Garcia‐Munoz, S. Martinez‐Pasamar, S. Inoges, A. Lopez‐Diaz de Cerio, and R. Palacios, et al. 2008. IL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. European Journal of Immunology. 38(2):576–86. Martinez‐Forero, I., R. Garcia‐Munoz, S. Martinez‐Pasamar, S. Inoges, A. Lopez‐Diaz de Cerio, and R. Palacios, et al. 2008. IL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. European Journal of Immunology. 38(2):576–86.
35.
Zurück zum Zitat Braitch, M., and S.C. Constantinescu. 2010. The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued). 9(4):249–56. Braitch, M., and S.C. Constantinescu. 2010. The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued). 9(4):249–56.
36.
Zurück zum Zitat Matejčíková, Z., J. Mareš, H.P. Vranová, J. Klosova, V. Sladkova, J. Dolakova, et al. 2015. Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: A pilot study. Journal of Neural Transmission. 122 (2): 273–277.CrossRef Matejčíková, Z., J. Mareš, H.P. Vranová, J. Klosova, V. Sladkova, J. Dolakova, et al. 2015. Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: A pilot study. Journal of Neural Transmission. 122 (2): 273–277.CrossRef
37.
Zurück zum Zitat Dimisianos, N., M. Rodi, D. Kalavrizioti, V. Georgiou, P. Papathanasopoulos, A. Mouzaki. 2014. Cytokines as biomarkers of treatment response to IFNβ in relapsing-remitting multiple sclerosis. Multiple Sclerosis International. 2014;2014. Dimisianos, N., M. Rodi, D. Kalavrizioti, V. Georgiou, P. Papathanasopoulos, A. Mouzaki. 2014. Cytokines as biomarkers of treatment response to IFNβ in relapsing-remitting multiple sclerosis. Multiple Sclerosis International. 2014;2014.
38.
Zurück zum Zitat Trenova, A.G., G.S. Slavov, M.G. Manova, and I.I. Kostadinova. 2014. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis. Archives of medical research. 45 (6): 495–500.CrossRef Trenova, A.G., G.S. Slavov, M.G. Manova, and I.I. Kostadinova. 2014. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis. Archives of medical research. 45 (6): 495–500.CrossRef
39.
Zurück zum Zitat Lu, L.-F., M.P. Boldin, A. Chaudhry, L.-L. Lin, K.D. Taganov, T. Hanada, et al. 2010. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142 (6): 914–929.CrossRef Lu, L.-F., M.P. Boldin, A. Chaudhry, L.-L. Lin, K.D. Taganov, T. Hanada, et al. 2010. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142 (6): 914–929.CrossRef
40.
Zurück zum Zitat Tang, Y., X. Luo, H. Cui, X. Ni, M. Yuan, Y. Guo, et al. 2009. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 60 (4): 1065–1075.CrossRef Tang, Y., X. Luo, H. Cui, X. Ni, M. Yuan, Y. Guo, et al. 2009. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 60 (4): 1065–1075.CrossRef
41.
Zurück zum Zitat Alexandrov, P.N., P. Dua, and W.J. Lukiw. 2014. Up-regulation of miRNA-146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS. Frontiers in neurology. 5: 181.CrossRef Alexandrov, P.N., P. Dua, and W.J. Lukiw. 2014. Up-regulation of miRNA-146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS. Frontiers in neurology. 5: 181.CrossRef
42.
Zurück zum Zitat Yu, J.-H., L. Long, Z.-X. Luo, L.-M. Li, and J.-R. You. 2016. Anti-inflammatory role of microRNA let-7c in LPS treated alveolar macrophages by targeting STAT3. Asian Pacific journal of tropical medicine. 9 (1): 72–75.CrossRef Yu, J.-H., L. Long, Z.-X. Luo, L.-M. Li, and J.-R. You. 2016. Anti-inflammatory role of microRNA let-7c in LPS treated alveolar macrophages by targeting STAT3. Asian Pacific journal of tropical medicine. 9 (1): 72–75.CrossRef
43.
Zurück zum Zitat Satoh, J.I., Y. Kino, and S. Niida. 2015. MicroRNA-Seq data analysis pipeline to identify blood biomarkers for Alzheimer’s disease from public data. Biomarker Insights. 10:BMI. S25132. Satoh, J.I., Y. Kino, and S. Niida. 2015. MicroRNA-Seq data analysis pipeline to identify blood biomarkers for Alzheimer’s disease from public data. Biomarker Insights. 10:BMI. S25132.
44.
Zurück zum Zitat Zhang, Y., C. Liu, J. Wang, Q. Li, H. Ping, S. Gao, et al. 2016. MiR-299-5p regulates apoptosis through autophagy in neurons and ameliorates cognitive capacity in APPswe/PS1dE9 mice. Scientific reports. 6 (1): 1–14.CrossRef Zhang, Y., C. Liu, J. Wang, Q. Li, H. Ping, S. Gao, et al. 2016. MiR-299-5p regulates apoptosis through autophagy in neurons and ameliorates cognitive capacity in APPswe/PS1dE9 mice. Scientific reports. 6 (1): 1–14.CrossRef
45.
Zurück zum Zitat Azarbarzin, S., M.A.H. Feizi, R. Safaralizadeh, R. Ravanbakhsh, M. Kazemzadeh, A. Fateh, et al. 2016. The value of miR-299-5p in diagnosis and prognosis of intestinal-type gastric adenocarcinoma. Biochemical genetics. 54 (4): 413–420.CrossRef Azarbarzin, S., M.A.H. Feizi, R. Safaralizadeh, R. Ravanbakhsh, M. Kazemzadeh, A. Fateh, et al. 2016. The value of miR-299-5p in diagnosis and prognosis of intestinal-type gastric adenocarcinoma. Biochemical genetics. 54 (4): 413–420.CrossRef
46.
Zurück zum Zitat Majd, M., A. Hosseini, K. Ghaedi, A. Kiani-Esfahani, S. Tanhaei, H. Shiralian-Esfahani, et al. 2018. MiR-9-5p and miR-106a-5p dysregulated in CD4+ T-cells of multiple sclerosis patients and targeted essential factors of T helper17/regulatory T-cells differentiation. Iranian journal of basic medical sciences. 21 (3): 277.PubMedPubMedCentral Majd, M., A. Hosseini, K. Ghaedi, A. Kiani-Esfahani, S. Tanhaei, H. Shiralian-Esfahani, et al. 2018. MiR-9-5p and miR-106a-5p dysregulated in CD4+ T-cells of multiple sclerosis patients and targeted essential factors of T helper17/regulatory T-cells differentiation. Iranian journal of basic medical sciences. 21 (3): 277.PubMedPubMedCentral
47.
Zurück zum Zitat Rahimirad, S., M. Navaderi, S. Alaei, and M.H. Sanati. 2021. Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis. Neurological Sciences. 2021:1–9. Rahimirad, S., M. Navaderi, S. Alaei, and M.H. Sanati. 2021. Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis. Neurological Sciences. 2021:1–9.
Metadaten
Titel
Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients
verfasst von
Marjan Golabi
Farshid Fathi
Morteza Samadi
Mohammad Sadegh Hesamian
Nahid Eskandari
Publikationsdatum
28.03.2022
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2022
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-022-01662-9

Weitere Artikel der Ausgabe 4/2022

Inflammation 4/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.